Applied Therapeutics Shares Hit 52-Week High on Govorestat Filings
By Colin Kellaher
Applied Therapeutics shares rose sharply and hit a new 52-week high on Wednesday after the clinical-stage biopharmaceutical company reported a pair of regulatory advances for its lead product candidate.
Shares of the New York company were recently changing hands at $3.98, up 9.2%, after touching a 52-week high of $4.42 earlier in the session.
Applied said it filed last month for U.S. Food and Drug Administration approval of govorestat for the treatment of classic galactosemia, a rare genetic metabolic disease for which there is currently no available treatment.
The company also said the European Medicines Agency has validated and accepted for review its application seeking approval of the drug in the European Union.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 03, 2024 11:05 ET (16:05 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Morningstar’s Guide to Investing in Stocks
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst